<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <meta name="content" description="">


   <!--google fonts-->
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400,600,700|Roboto:400,500,700,900" rel="stylesheet">

    <!--favicon here-->
    <link rel="icon" href="img/favicon.ico" type="image/ico" sizes="16x16">
    

    <!--all external libraries goes here--> 
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/font-awesome.min.css">

    <link rel="stylesheet" href="css/slick.css">
    <link rel="stylesheet" href="css/slick-theme.css">

    <!--custom css-->
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/responsive.css">

    
    <!--place scripts after stylesheets-->
   
    <script src="js/jquery.min.js"></script>
     <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-circle-progress/1.2.2/circle-progress.min.js"></script>
     <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-cookie/1.4.1/jquery.cookie.min.js"></script>

     <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-5ZZJ6BQ');</script>
        <!-- End Google Tag Manager -->
    <title>Keytruda | Keynote 054</title>
    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
      j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
      'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-KT8KRGD');</script>
    <!-- End Google Tag Manager -->
  </head>
  <body> 
      <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5ZZJ6BQ"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KT8KRGD"
                        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
        <span class="scroller-fixed-height"> 
         
    </span> 

    <div id="linedraw-wrapper">
        <div class="progress-container">
            <div class="progress-bar" id="myBar"></div>
        </div> 
    </div>
    <!--==========================site header starts here=====================================-->
    <header class="header w-100 fixed-top" id="siteHeader">
        <div class="top-header bg-white">
            <div class="container"> 
                <div class="row">  

                    <div class="col-lg-6 col-md-5 text-left desktop-only">  
                        <img src="img/logo.png" alt="Logo" class="img-fluid pointer" onclick="window.location.href='index.html'">
                    </div><!--end logo holder-->
					 <div class="col-lg-6 col-md-5 mobilelogo">  
						<img src="img/Keytruda-logo.png" alt="Logo" class="pointer" onclick="window.location.href='index.html'">
                    </div><!--end logo holder-->

                    <div class="col-lg-6 col-md-7 text-right my-auto">  
                        <ul class="list-unstyled list-inline mb-0">    
                            <li class="list-inline-item"><a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf" target="_blank"><img src="img/header-icon1.png" alt="header-icon" class="img-fluid"> Product Monograph</a></li>

                            <li class="list-inline-item"><a href="#" data-toggle="modal" data-target="#safety-popup"><img src="img/header-icon2.png" alt="header-icon"> Safety Information</a></li>

                            <li class="french-button"> 
                                <a href="fr/index.html">Fran√ßais</a> 
                            </li> 

                        </ul>
                    </div><!--end col md4--> 
                </div><!--end row-->
            </div><!--end contianer-->
        </div><!--end top header-->

        <div class="navigation back-primary">
            <div class="container" style="padding:0;">
                <nav class="navbar navbar-expand-md back-primary navbar-dark custom-navbar">
                 
                  <div class="custom-navigation w-100">   

                    <div class="d-flex justify-content-between align-items-center mobile-ipad-only-flex">
                        <img src="img/logo-white.png" alt="logo">
                        <i class="fas fa-bars" onclick="openNav()" class="mobile-ipad-only"></i> 
                    </div><!--end mobile ipad only-->  

                    <div id="mySidenav" class="sidenav mobile-ipad-only">
                      <a href="javascript:void(0)" class="closebtn" onclick="closeNav()">&times;</a>
                      <a href="#" id="#section-1"  class="mobile-links">KEYTRUDA<sup>&reg;</sup></a>
                      <a href="#" id="#section-2"  class="mobile-links">Efficacy</a>
                      <a href="#" id="#section-3"  class="mobile-links">Safety Profile</a>
                      <a href="#" id="#section-4"  class="mobile-links">Dosing</a>
                      <a href="#" id="#section-5"  class="mobile-links">Contact us</a>
                    </div><!--end mobile navigation-->
                 

                    <ul class="navbar-nav custom-nav desktop-only-flex nav-carousel-mobile">

                      <li class="nav-item">
                        <a class="nav-link scroll" href="#section-1"> <span><img src="img/melan-icon.png" alt="Keytruda experience"></span> KEYTRUDA<sup>&reg;</sup></a>
                      </li>

                      <li class="nav-item">
                        <a class="nav-link scroll" href="#section-2"> <span><img src="img/nav-icon2.png" alt="Efficacy"></span> Efficacy</a>
                      </li>


                      <li class="nav-item">
                        <a class="nav-link scroll" href="#section-3"> <span><img src="img/nav-icon3.png" alt="safety"></span> Safety Profile</a>
                      </li>

                      <li class="nav-item">
                        <a class="nav-link scroll" href="#section-4"> <span><img src="img/nav-icon4.png" alt="Dosing"></span> Dosing</a>
                      </li>

                      <li class="nav-item">
                        <a class="nav-link scroll" href="#section-5"> <span><img src="img/nav-icon6.png" alt="Oncology Program"></span> Merck care<sup>tm</sup> Oncology Program</a>
                      </li>  

                    </ul><!--end navbar nav-->
					<button type="button" class="mobile_scroll_btn pn-Advancer_Left" id="pnAdvancerLeft"><img src="img/left-arrow.png" alt="left-arrow"></button> 
                    <button type="button" class="mobile_scroll_btn pn-Advancer_Right" id="pnAdvancerRight"><img src="img/right-arrow.png" alt="right-arrow"></button>
                  </div><!--end collapse-->

                </nav><!--end navigation-->
            </div><!--end container-->
        </div><!--end navigation-->
    </header><!--end header-->
    <!--==========================site header starts here=====================================-->

    <!--==========================site main body starts here=====================================-->
    <main class="main-body w-100" id="siteBody">
        <!--section start-s here-->
        <section class="banner-section w-100 background-properties">

            <div class=" w-100">
                <div class="container banner_head">
                    <div class="row">
                        <div class="col-lg-6 col-md-7 col-12">
							<div class="banner_box">
								<div class="banner-message banner_box_xs_hide">
									<h1 class="brand-color banner-heading font-weight-bold">KEYTRUDA<sup>&reg;</sup>: New indication in adjuvant treatment of stage III melanoma</h1>
									<p class="text-lighter"><sup>Pr</sup>KEYTRUDA<sup>&reg;</sup> (pembrolizumab) is indicated for the adjuvant treatment of patients with stage III melanoma with lymph node involvement who have undergone complete resection.<sup>1</sup></p>
									<div class="skip_keynote_mob">
										<a href="#down-keynote">Skip to KEYNOTE-054 study</a><a href="#down-keynote"></a><a href="#donw-keynote"><img src="img/down_arow.png" alt="down_arow"></a>
									</div>
								</div><!--end banner message-->
							</div>
                        </div><!--end banner content col-->
                    </div><!--end row-->
					<div class="skit_arrow">
                    <a href="#down-keynote">						
						<p>Skip to KEYNOTE-054 study</p>
						<img src="img/skip-arrow.png" alt="skip-arrow">	
                        </a>				
					</div>
                </div><!--end container-->
            </div><!--end banner content-->
        </section><!--end banner section-->
        <!--secton ends here-->
            <div class="xs_visi_under_banner_txt"> 
            </div>  
        <!--section start-s here-->
        <section class="subheading-section w-100 py-5 under-banner-sec-demons">
            <div class="container subheading-section-container">
                <div class="row risk_of_death_sec">
                    <div class="col-md-12 col-12 col-lg-10">
                        <div class="subheading-left-section pr-md-0">
                            <h3 class="brand-color mb-4">KEYTRUDA<sup>¬Æ</sup> demonstrated a significant improvement in recurrence-free survival (RFS) vs. placebo in patients with resected stage III melanoma</h3>
							<h4>(135 vs. 216 events; HR<sup>*</sup>=0.57 [98% CI: 0.43-0.74]; P<0.0001<sup>‚Ä†</sup>)<sup>1</sup></h4>
						
                        </div><!--end left section-->
                    </div><!--end col-->
                    
                </div><!--end row-->
                <div class="row" style="margin-top:30px;">
                     <div class="col-md-10 col-12 col-lg-6">
                        <div class="row response-chart-holder second_chart_holder response-chart-white">
                            <div class="container-fluid">
                                <div class="plat_pem_sec">
                                    <h3 class="keytruda_plat_text w-100 text-center">RFS at 1 year:</h3>
                                    
                                </div>
                                
                            <div class="left-chart-response col text-center">
                                <div class="progressbar3" data-animate="false">
                                <div class="circle3" data-percent="75">
                                <div></div>
                                </div> 
                                </div>
                                <h6 class="text-second mt-1">with KEYTRUDA<sup>¬Æ</sup></h6>
                            </div><!--end left chart response-->


                            <div class="right-chart-response col text-center">
                                 <!-- <img src="img/chart-2-graph.png" alt="chart" class="img-fluid"> -->
                                 <!-- <div class="chart2" data-size="130" data-value="49"></div> -->
                                  <div class="progressbar4" data-animate="false">
                                    <div class="circle4" data-percent="61">
                                    <div></div>
                                    </div> 
                                    </div>
                                 <h6 class="text-second mt-1">with placebo</h6>
                                 <div class="vs_text"><span class="chart_vs">vs</span></div>
                            </div><!--end right chart response-->
                            </div>
                        </div><!--end flex container-->
                    </div><!--end col-->

            
                    <div class="col-md-10 col-12 col-lg-6">
                            <div class="risk_of_death_present campare_sec_present_button mt-4">
                            <div class="box_bottom_img">
                                <img src="img/bottom_green_box.png" alt="bottom_green_box">
                            </div>
                            <div class="present_box">
                                <h3><img src="img/down-arrow.png" alt="down-arrow">43% <span>reduction in the risk of recurrence or death</span></h3>
                            </div>  
                        </div> 
                        </div>
                  <div class="col-md-12">
                    <p class="text-lighter"><span>* </span> Based on the stratified Cox proportional hazard model.</p>
                    <p class="text-lighter">‚Ä† P-value (based on stratified log rank test) is compared with 0.008 of the allocated alpha for this interim analysis.</p>
                  </div>
                </div>
                 <div class="row">
                            <div class="col-12 col-lg-6 col-md-10">
                             <div class="subheading-right-section px-lg-3 px-md-0">
                              <div class="reduction-block px-2 pl-4 d-flex align-item-center present_div_desk">
                                    <h2 class="mb-0"><img src="img/down-arrow.png" alt="down-arrow"> 43%<span>reduction in the risk of recurrence or death</span></h2>
                                </div>
                        </div><!--end right section-->
                        </div>
                        </div>

                
            </div><!--end container-->
            
        </section><!--end content section-->
        <!--secton ends here-->

        <!--section starts here-->
        <section id="section-1" class="page-banner-content keytruda-experience w-100 background-properties back-effect line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white">
                    <div class="row">
                        <div class="col-lg-10 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle" id="lineStarter"></span>KEYTRUDA<sup>¬Æ</sup> Indications in Adjuvant <br>Stage III Melanoma and in Unresectable and Metastatic Melanoma</h2>
                           <!--  <p class="page-lead">A New Option for Adjuvant Stage III Melanoma Patients
                                    KEYTRUDA is now indicated in the adjuvant setting: resected Stage IIIA, B and C melanoma, regardless of BRAF status.<sup>1</sup></p> -->
                        </div><!--end col md-->

                        <div class="col-lg-4 offset-lg-1 content-right col-md-5 offset-md-0">
                        </div><!--end banner accordion section-->
                    </div><!--end row-->
                </div><!--end container-->
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 patient line-common-section Expanding">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-12 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> New Indication in Adjuvant Treatment of Stage III Melanoma<sup>1</sup></h2>
                        <!-- <p class="common-text">Now, you can turn to KEYTRUDA<sup>¬Æ</sup> for adjuvant therapy after complete resection.</p> -->
                    </div><!--end col-->
                </div><!--end row-->
                
                <div class="row expanding-mobile-only">

                    <div class="col-lg-4 col-12 col-md-4 col-sm-12 active-expanding">
                        <div class="row">
                            <div class="col-12">
                                <h4 class="secondary-page-header text-center expanding-heading">ADJUVANT TREATMENT OF STAGE III RESECTED MELANOMA</h4>
                            </div><!--end col 12-->
                        </div><!--end upper heading-->    
                        <div class="row">
                            <div class="col-12 col-lg-12">
                                <div class="left-gray p-4">
                                    <p>For the adjuvant treatment of patients with Stage III melanoma with lymph node involvement who have undergone <strong>complete resection.</strong></p>    
                                </div><!--edn left gray-->
                            </div><!--end first block-->
                        </div><!--end row-->
                    </div><!--end right side block-->

                    <div class="col-lg-4 col-12 col-md-4 col-sm-12">
                        <div class="row">
                            <div class="col-12">
                                <h4 class="secondary-page-header text-center expanding-heading">UNRESECTABLE OR METASTATIC MELANOMA (IPILIMUMAB-NA√èVE)</h4>
                            </div><!--end col 12-->
                        </div><!--end upper heading-->        
                        <div class="row">
                            <div class="col-12 col-lg-12">
                                <div class="left-gray p-4">
                                    <p>For the treatment of patients with unresectable or <strong>metastatic melanoma</strong> who have <strong>not received prior treatment</strong> with ipilimumab. BRAF V600 mutant melanoma patients may have received prior BRAF inhibitor therapy. 
                                        </p>                            
                                </div><!--edn left gray-->
                            </div><!--end first block-->
                        </div><!--end row-->
                    </div><!--end right side block-->

                    <div class="col-lg-4 col-12 col-md-4 col-sm-12">
                        <div class="row">
                            <div class="col-12">
                                <h4 class="secondary-page-header text-center expanding-heading">UNRESECTABLE OR METASTATIC MELANOMA (WITH DISEASE PROGRESSION FOLLOWING IPILIMUMAB TREATMENT)</h4>
                               
                            </div><!--end col 12-->
                        </div><!--end upper heading-->
                        <div class="row">
                            <div class="col-12 col-lg-12">
                                <div class="left-gray p-4">
                                    <p>For the treatment of patients with unresectable or <strong>metastatic melanoma and disease progression</strong> following ipilimumab therapy and, if BRAF V600 mutation +, following a BRAF or MEK inhibitor.</p>
                                    
                                </div><!--edn left gray-->
                            </div><!--end first block-->
                        </div><!--end row-->
                    </div><!--end right side block-->
                </div>

                <div class="row expanding-desktop-only expanding_table_wrapper">
                    <div class="col-12">
                        <div class="table-responsive">
                           <table class="hand-icon-table">
                              <tbody><tr class="table_head_row">
                                <th class="table_heading">ADJUVANT TREATMENT OF STAGE III RESECTED MELANOMA</th>
                                <th class="table_heading">UNRESECTABLE OR METASTATIC MELANOMA (IPILIMUMAB-NA√èVE)</th>
                                <th class="table_heading">UNRESECTABLE OR METASTATIC MELANOMA (WITH DISEASE PROGRESSION FOLLOWING IPILIMUMAB TREATMENT)</th>
                              </tr>
                              <tr class="odd">
                                <td class="expanding-active">For the <strong class="semi-bold">adjuvant treatment</strong> of patients with Stage III melanoma with lymph node involvement who have undergone <strong class="semi-bold">complete resection.</strong></td> 
                                <td>For the treatment of patients with unresectable or <strong class="semi-bold">metastatic melanoma</strong> who have <strong class="semi-bold">not received prior treatment</strong> with ipilimumab. BRAF V600 mutant melanoma patients may have received prior BRAF inhibitor therapy.</td>
                                <td>For the treatment of patients with unresectable or <strong class="semi-bold">metastatic melanoma and disease progression</strong> following ipilimumab therapy and, if BRAF V600 mutation +, following a BRAF or MEK inhibitor.</td>
                              </tr>                                   
                            </tbody></table>
                        </div>
                    </div>
                </div>
							
            </div><!--end container-->
        </section><!--end page banner content section-->
        <!--section ends here-->

         <!--section starts here-->
        <section id="section-2" class="page-banner-content w-100 background-properties back-effect light efficacy line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white py-5 py-100-fixer">
                    <div class="row">
                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span> Efficacy</h2>
                            <p class="page-lead">In this section, the design of the pivotal study KEYNOTE-054, which evaluated KEYTRUDA<sup>&reg;</sup> in the adjuvant treatment of completely resected Stage III melanoma, is presented. Baseline characteristics that describe the study population are outlined. The efficacy data for the primary endpoint ‚Äì investigator-assessed RFS ‚Äì are also presented.</p>
                        </div><!--end col md-->

                        <div class="col-lg-4 col-md-6 offset-lg-1 offset-md-0 content-right mt-md-3 mt-lg-0 mt-sm-0 mt-0">
                            <ul class="banner-section-listing">
                                <li><a href="#down-keynote">Study Design</a></li>
                                <li><a href="#baseline-link">Baseline Characteristics</a></li>
                                <li><a href="#overall-link">Recurrence-free Survival</a></li>
                           
                            </ul><!--end banner section listing-->
                        </div><!--end banner accordion section-->
                        <span id="down-keynote" class="link-grabber"></span> 
                    </div><!--end row-->
                </div><!--end container-->
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

         <!--section starts here-->
        <section class="page-common-section w-100 keynote line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span>Study Design</h2>
                        <p class="common-text">KEYNOTE-054 is a pivotal multicentre, randomized, double-blind, placebo-controlled trial that evaluated the efficacy of KEYTRUDA<sup>&reg;</sup> in patients with completely resected stage III melanoma.<sup>1,2</sup></p>
                    </div><!--end col-->
                </div><!--end row-->                

                <div class="row my-5 mobile-ipad-only">
                    <div class="col-12">
                        <div class="slider-mobile-only">

                            <div class="step-m-1">
                                 <div class="steps mb-3">
                                    <span>1</span>
                                    <h5>Inclusion Criteria</h5>
                                </div><!--end steps-->

                                <div class="step-1 align-items-center d-flex py-2 px-3">

                                    <ul class="step-1-list list-unstyled">
                                        <li>Stage IIIA (>1mm lymph node metastasis), IIIB or IIIC melanoma</li>
                                        <li>Had undergone lymph node dissection, and if indicated, radiotherapy within 13 weeks prior to starting treatment</li>
                                        
                                    </ul><!--end step1 listing-->
                                </div><!--end step1-->
                            </div><!--end content-->

                            <div class="two-stepper-holder">
                                <div class="steps mb-3">
                                    <span>2</span>
                                    <h5>Study Arms</h5>
                                </div><!--end steps-->
    
                                <div class="left-step-section text-center">
                                    <img src="img/circle-melo-mobile.png" alt="chart" class="img-fluid">
                                </div><!--end left step section-->

                                <div class="step-2 d-flex  align-items-center py-4">

                                    <div class="right-step-section">
                                        <div class="top-block">
                                          
                                            <p class="primary-block common-text-block back-primary text-white">
                                                KEYTRUDA<sup>¬Æ</sup> 200 mg every 3 weeks (n=514)
                                            </p>
                                        </div><!--end top block-->

                                        <div class="top-block mt-11">
                                           
                                            <p class="white-block common-text-block bg-white text-second">
                                               PLACEBO (n=505)
                                            </p>
                                        </div><!--end top block-->
                                    </div><!--end right step section-->
                                </div><!--end step2-->
                            </div><!--end step2 content-->

                            <div>
                                <div class="step-3 p-3 d-flex flex-column justify-content-center primary-grey-part">
                                    <div class="steps mb-3">
                                        <span>3</span>
                                        <h5>Primary Endpoints<sup>‚Ä†</sup></h5>
                                    </div><!--end steps-->

                                    <div class="top-step-section">
                                        <p class="sec_end_sub">Investigator-assessed RFS (ITT population) <br>+<br> Investigator-assessed RFS (PD-L1 positive subgroup)</p>
                                        
                                    </div><!--end top section-->

                                </div><!--end step3-->
                            </div><!--end step3 content-->

                            <!-- <div>
                                <div class="step-4 p-4 d-flex flex-column justify-content-center">
                                    <div class="steps mb-3">
                                        <span>4</span> 
                                        <h5>Key Secondary Endpoints<sup>‚Ä†</sup></h5>
                                    </div>
                                    <div class="top-step-section"> 
                                        <p class="sec_end_sub">Distant metastasis-free survival <br> Overall survival</p>
                                        
                                    </div>

                                </div>
                            </div> -->

                        </div><!--end slider for mobile devices-->
                    </div><!--end col 12-->
                </div><!--end mobile stepper tabbed-->

                <div class="row my-5 desktop-only-flex" id="stepper-display">
                    <div class="col-12">
                        <div class="steps-header mb-3 d-flex">

                            <div class="steps">
                                <span>1</span>
                                <h5>Inclusion Criteria</h5>
                            </div><!--end steps-->

                            <div class="steps">
                                <span class="line"></span>
                                <span class="study_arm_step">2</span>
                                <h5>Study Arms</h5>
                            </div><!--end steps-->

                            <div class="steps">
                                <span>3</span>
                                <h5>Primary Endpoints<sup>‚Ä†</sup></h5>
                            </div><!--end steps-->

                        </div><!--end steps-->
                    </div><!--end steps-->

                    <div class="col-12">
                        <div class="stepper-ui d-sm-flex">
                            
                            <div class="step-1 align-items-center d-flex px-4">
                                <ul class="step-1-list list-unstyled">
                                    <li>Stage IIIA <br>(>1mm lymph node metastasis), IIIB or IIIC melanoma</li>
                                    <li>Had undergone lymph node dissection, and if indicated, radiotherapy within 13 weeks prior to starting treatment</li>
                                </ul><!--end step1 listing-->
                            </div><!--end step1-->

                            <div class="step-2 d-flex align-items-center px-lg-5 pl-md-4 pr-md-3 py-4">
                                <div class="left-step-section">
                                    <img src="img/melona-study.png" alt="chart" class="img-fluid">
                                </div><!--end left step section-->

                                <div class="right-step-section pl-lg-4 pl-md-0">
                                    <div class="top-block">
                                       
                                        <p class="primary-block common-text-block back-primary text-white">
                                            <strong class="semi-bold">KEYTRUDA<sup>¬Æ</sup></strong> 200 mg every 3 weeks (n = 514)
                                        </p>
                                    </div><!--end top block-->

                                    <div class="top-block mt-1">
                                     
                                        <p class="white-block common-text-block bg-white text-second">
                                         <strong class="semi-bold">PLACEBO</strong> (n = 505)
                                        </p> 
                                    </div><!--end top block--> 
                                </div><!--end right step section-->
                            </div><!--end step2-->

                            <div class="step-3 px-3 d-flex flex-column justify-content-center">


                                <div class="bottom-step-section ">                                
									<p class="sec_end_sub">Investigator-assessed RFS<br>(ITT population)</p>
                                    <p class="sec_end_sub text-left">+</p>
                                    <p class="sec_end_sub">Investigator-assessed RFS<br>(PD-L1 positive subgroup)</p>
                                </div><!--end top section-->

                            </div><!--end step3-->
                        </div><!--end stepper ui-->
                    </div><!--end col12-->
                </div><!--end row-->

                <div class="row mt-5 main_service_div">
                    <div class="col-sm-12 col-md-6 col-lg-3 study_service_content">
			<p>Treatment continued until disease progression or unacceptable toxicity up to a maximum of <span class="line_breaker"><strong class="semi-bold">1 year.</strong><sup>1</sup></span></p>
                    </div><!--end col sm4-->

                     <div class="col-sm-12 col-md-6 col-lg-3 study_service_content">
						<p>RFS was defined as time between randomization and <strong class="semi-bold">first recurrence</strong> (local, regional or distant metastasis) <strong class="semi-bold">or death</strong>, whichever occurred first.<sup>1</sup></p>
                    </div><!--end col sm4-->

                     <div class="col-sm-12 col-md-6 col-lg-3 study_service_content">
                        <p>KEYTRUDA<sup>¬Æ</sup> could be <strong class="semi-bold">reinitiated</strong> for subsequent disease reoccurence >6 months after completing 1 year of adjuvant treatment.<sup>1</sup></p>
                    </div><!--end col sm4-->

                    <div class="col-12 col-lg-8 mt-ipad-setting col-md-10 mt-4">
                      <div class="response_detail_list">
                        <ul>
                            <li><p>* Stratified by American Joint Committee on Cancer 7th edition stage (IIIA vs. IIIB vs. IIIC 1-3 positive lymph nodes vs. IIIC ‚â•4 positive lymph nodes) and geographic region (North America, European countries, Australia, and other countries as designated).<sup>1</sup></p></li>
                            <li><p>‚Ä† Imaging was conducted every 12 weeks during the first 2 years, every 6 months in years 3-5, and annually thereafter.<sup>1</sup></p></li>
                       
                        </ul>
                      </div>
                      
                    </div>


                </div><!--end row-->
            </div><!--end container-->
            <span id="baseline-link" class="link-grabber"></span>
        </section><!--end page banner content section-->
        <!--section ends here-->

         <!--section starts here-->
        <section class="page-banner-content w-100 baseline-section background-properties line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-green py-5 pos-rel py-100-fixer">
                        
                    <div class="row">
                       
                             <span class="top-redirect-arrow" id="redirectArrow"><img src="img/arrow-content.png" alt="Go Top"></span> 
                       
                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header brand-color"><span class="pulsating-circle"></span> Baseline Characteristics</h2>
                           <!--  <p class="page-lead text-second">Stage IIIA, IIIB and IIIC patients, regardless of BRAF mutation status, were included in the trial.<sup>1</sup></p> -->
                           
                           <div class="chart-img-holder baseline_table mt-5 mb-4 w-100 ">
							<div class="table-responsive">
                               <table class="hand-icon-table">
								  <tr class="table_head_row">
									<th class="table_heading"></th>
									<th class="table_heading">KEYTRUDA<sup>¬Æ</sup><br/>200 mg every 3 weeks n=514</th>
									<th class="table_heading">Placebo n=505</th>
								  </tr>
								  <tr class="odd">
									<td>Men</td>
									<td>63%</td>
									<td>60%</td>
								  </tr> 
								  <tr class="even">
									<td>Women</td>
									<td>37%</td>
									<td>40%</td>
								  </tr>
								   <tr class="odd">
									<td>Age (median)</td>
									<td>54 years</td>
									<td>54 years</td>
								  </tr> 
								  <tr class="even">
									<td>Age (range)</td>
									<td>19-88 years</td>
									<td>19-83 years</td>
								  </tr>
                                  <tr class="odd">
                                    <td>Age (‚â• 65)</td>
                                    <td>24%</td>
                                    <td>25%</td>
                                  </tr> 
								  <tr class="table_chart_head">
									<td colspan="2">ECOG PS</td>
									<td></td>
								  </tr>
								   <tr class="odd">
									<td>0</td>
									<td>94%</td>
									<td>94%</td>
								  </tr>
								   <tr class="even">
									<td>1</td>
									<td>6%</td>
									<td>6%</td>
								  </tr> 
								   
								   <tr class="table_chart_head">
									<td colspan="2">Stage</td>
									<td></td>
								  </tr>
								  <tr class="even">
									<td>IIIA (> 1 mm)</td>
									<td>16%</td>
									<td>16%</td>
								  </tr>
								  <tr class="odd">
									<td>IIIB</td>
									<td>46%</td>
									<td>46%</td>
								  </tr>
                                  <tr class="even">
                                    <td>IIIC (1-3 positive lymph nodes)</td>
                                    <td>18%</td>
                                    <td>18%</td>
                                  </tr>
                                  <tr class="odd">
                                    <td>IIIC (‚â• 4 positive lymph nodes)</td>
                                    <td>20%</td>
                                    <td>20%</td>
                                  </tr>
								   <tr class="table_chart_head">
									<td colspan="2">BRAF Status</td>
									<td></td>
								  </tr>
								   <tr class="even">
									<td>Mutation Detected </td>
									<td>48%</td>
									<td>52%</td>
								  </tr>
								  <tr class="odd">
									<td>Mutation Not Detected</td>
									<td>45%</td>
									<td>42%</td>
								  </tr>
								   <tr class="even">
									<td>Unknown</td>
									<td>7%</td>
									<td>6%</td>
								  </tr>
								   <tr class="table_chart_head">
									<td colspan="3">PD-L1 Status<sup>*</sup></td>
								  </tr>
								  <tr class="odd">
									<td>Positive</td>
									<td>83%</td>
									<td>84%</td>
								  </tr>
								  <tr class="even">
									<td>Negative</td>
									<td>11%</td>
									<td>11%</td>
								  </tr>	
                                  <tr class="odd"> 
                                    <td>Unknown</td>
                                    <td>5%</td>
                                    <td>5%</td>
                                  </tr>
                                  <tr class="even">
                                    <td colspan="3" class="t-para">
                                        <ul>
                                            <li class="symbol-star">Assessed by immunohistochemistry; positive: ‚â•1% PD-L1; negative: <1% PD-L1; unknown: indeterminate PD-L1.<sup>1</sup></li>
                                            <li>ECOG PS=Eastern Cooperative Oncology Group performance status; PD-L1=programmed cell death ligand 1.</li>
                                            <li>Adapted from the KEYTRUDA<sup>&reg;</sup> Product Monograph.<sup>1</sup></li>
                                        </ul>
                                  </tr> 
								  
								</table>
								</div>
                           </div><!--end chart img holder-->

                           <div class="download_table">
        <a href="img/baseline_characteristics-updated.pdf" target="_blank" download class="btn button-second">
                                 Download Table <img src="img/download_table.png" alt="download_table"></a>
                                   <a href="#" class="zoom_icon" data-toggle="modal" data-target="#tableZoom"><img src="img/zoom_icon.png" alt="zoom"></a>

                                        <!-- Modal -->
                                        <div class="modal fade custom-zoom-modal" id="tableZoom" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
                                            <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                                <div class="modal-content">                      

                                                    <div class="modal-body">
                                                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                            <span aria-hidden="true">&times;</span>
                                                        </button>
                                                        <img src="img/baseline_characteristics-updated.jpg" alt="table" class="img-fluid">      
                                                    </div>               
                                                </div>
                                            </div>
                                        </div>

                           </div><!--end flexbox-->
                        </div><!--end col md-->
                    </div><!--end row-->
                </div><!--end container-->
                 
                 <span class="link-grabber" id="overall-link"></span>  
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 overall-servival line-common-section">
            <div class="container py-5 draw-green py-100-fixer">
                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Primary Endpoint: Recurrence-free Survival</h2>
                        <p class="common-text primary-part-text">KEYTRUDA<sup>&reg;</sup> <strong class="semi-bold">demonstrated a significant improvement</strong> in recurrence-free survival <strong class="semi-bold">(RFS) vs. placebo</strong> (<i>P</i>< 0.0001) in adjuvant treatment of patients with resected stage III melanoma. Median RFS was not reached with KEYTRUDA<sup>&reg;</sup> vs. 20.4 months in the placebo group (95% CI: 16.2, NR).<sup>1</sup></p> 
						
                    </div><!--end col-->
                </div><!--end row-->
					<div class="risk_of_death_present overall_all_present d-m-none">
								<div class="present_box">
									<h3><img src="img/down-arrow.png" alt="down-arrow">51% <span>reduction in the risk of death<sup>1</sup></span></h3>
								</div>
								<div class="box_bottom_img">
									<img src="img/bottom_green_box.png" alt="bottom_green_box">
								</div>
							</div>
                <div class="row overall_chart_sec">
                    <div class="col-12 col-md-12 pr-sm-2 col-lg-6">
                        <!--highchart generator-->
                      <!-- <div id="container" style="height: auto; min-width: 80%; width:100%;"></div> -->
					 <div class="mobile-chart-crawler">
           <div class="chart_sec mt-2">
                        <div class="chart_left_sec">
                            <div class="chart_detail">
                                <div class="chart_color_box">
                                    <span class="color_box"></span>
                                    <p>KEYTRUDA<sup>¬Æ</sup></p>
                                    
                                </div>
                                <div class="chart_color_box">
                                    <span class="color_box plat_pem_color_box"></span>
                                    <p>Placebo</p>
                                    
                                    
                                </div>
                            </div>
                        </div>
                        <div class="os_text_sec ostext_mobile">
                                <p><strong class="semi-bold">RFS (%)</strong></p>
                            </div>
                        <div class="chart_right_sec hand-icon-chart">
                            <div class="chart_list">
                                <ul class="chart_left_list"> 
                                    <li>100</li>
                                    <li><span>90</span></li>
                                    <li><span>80</span></li>
                                    <li><span>70</span></li>
                                    <li><span>60</span></li>
                                    <li><span>50</span></li>
                                    <li><span>40</span></li>
                                    <li><span>30</span></li>
                                    <li><span>20</span></li>
                                    <li><span>10</span></li>
                                    <li><span>0</span></li>
                                </ul>
                            </div>
                            <div class="chart_list">
                                <ul class="chart_bottom_list">
                                    <li class="manth_text"><strong>Months</strong></li>
                                    <li>3</li>
                                    <li>6</li>
                                    <li>9</li>
                                    <li>12</li>
                                    <li>15</li>
                                    <li>18</li>
                                    <li>21</li>
                                    <li>24</li>
                                </ul>
                            </div>
                            <div class="chart_code_text">
                                <p><strong class="semi-bold">HR<sup>*</sup>=0.57 (98% CI: 0.43-0.74), P<0.00001<sup>‚Ä†</sup></strong></p>
                            </div>
                            <div class="chart_main_img_sec">
                                <div class="chart_detail_img">
                                    <img class="chart_green_img" src="img/chart-mela.png" alt="chartimg"> 
                                </div>
                            </div> 
                            <div class="os_text_sec">
                                <p><strong class="semi-bold">RFS (%)</strong></p>
                            </div>
                            
                        </div>
                      </div>
                      
                      <div class="number_at_rist_sec">
                        <h3 class="number_risk_head">Number at risk </h3>
                        <div class="number_box">
                            <table>
                              <tbody>
                                <tr class="border-0">
                                    <td colspan="10" class="text-left">KEYTRUDA<sup>¬Æ</sup>:</td>
                                </tr>
                                  <tr class="number_at_risk_row1">
                                    <td>514</td>
                                    <td>438</td>
                                    <td>413</td>
                                    <td>392</td>
                                    <td>313</td>
                                    <td>182</td>
                                    <td>73</td>
                                    <td>15</td>
                                    <td>0</td>
                                  </tr> 
                                 <tr class="border-0">
                                    <td colspan="10" class="text-left">Placebo:</td>
                                </tr>
                                  <tr class="number_at_risk_row2">
                                    <td>505</td>
                                    <td>415</td>
                                    <td>363</td>
                                    <td>323</td>
                                    <td>264</td>
                                    <td>157</td>
                                    <td>60</td>
                                    <td>15</td>
                                    <td>0</td>
                                  </tr>  
                              </tbody>
                              </table>
                        </div>
                        <p class="chart-content-small">Adapted from the KEYTRUDA<sup>&reg;</sup> Product Monograph.<sup>1</sup></p>
                        
                      </div>               
                     </div>
                        
                         <div class="chart_download">
                            <a href="img/Recurrence-Free-Survival.pdf" target="_blank" download class="download-table-button">
                                
                                Download Graph
                                <img src="img/download_table.png" alt="download_table">
                            </a>
                            <a href="#" data-toggle="modal" data-target="#graphZoom1">
                                <img src="img/zoom_icon.png" alt="zoom">
                            </a>
                            <!-- Modal -->
                            <div class="modal fade custom-zoom-modal" id="graphZoom1" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
                                    <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                        <div class="modal-content">
    
                                            <div class="modal-body rounded-modal">
                                                <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                    <span aria-hidden="true">√ó</span>
                                                </button>
                                                <img src="img/primary-recurrence-chart.png" alt="table" class="img-fluid">
                                            </div>
                                        </div>
                                    </div>
                            </div>
                        </div>



					  
					  <div class="number_at_rist_sec number_at_rist_sec_mob">
						<div class="number_box">
							<table>
							  <tbody>
								  <tr class="number_rist_td">
									<td colspan="7">Keytruda<sup>&reg;</sup>:</td>
								  </tr>
								  <tr class="number_keytruda_td">
									<td colspan="7">Placebo:</td>
								  </tr>
								  <tr class="number_at_risk_text">
									<td>514</td>
									<td>438</td>
									<td>413</td>
									<td>392</td>
									<td>313</td>
									<td>182</td>
									<td>73</td>
                                    <td>15</td>
									<td>0</td>
								  </tr>
								<tr class="number_plat_td">
									<td colspan="7">Placebo:</td>
								  </tr>								  
								 <tr class="number_at_risk_text_row">
									<td>505</td>
									<td>415</td>
									<td>363</td>
									<td>323</td>
									<td>264</td>
									<td>157</td>
									<td>60</td>
                                    <td>15</td>
									<td>0</td>
								  </tr> 
							  </tbody>
							  </table>
                            </div>
                            <p class="chart-content-small">Adapted from the KEYTRUDA<sup>&reg;</sup> Product Monograph.<sup>1</sup></p>

                              <div class="chart_download">
                            <a href="img/recurrence-free-survival.pdf" download target="_blank" class="download-table-button">                                     
                                Download Graph
                                <img src="img/download_table.png" alt="download_table">
                            </a>
                            <a href="#" data-toggle="modal" data-target="#graphZoom1" class="zoom-btn">
                                <img src="img/zoom_icon.png" alt="zoom">
                            </a>
                             <!-- Modal -->
                             <div class="modal fade custom-zoom-modal" id="graphZoom1" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
                                    <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                        <div class="modal-content">
    
                                            <div class="modal-body rounded-modal">
                                                <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                    <span aria-hidden="true">√ó</span>
                                                </button>
                                                <img src="img/primary-recurrence-chart.png" alt="table" class="img-fluid">
                                            </div>
                                        </div>
                                    </div>
                            </div>
                        </div>

					  </div>
                      

                      <div class="risk_of_death_present overall_all_present d-m-block seperate-death-present">
                                <div class="present_box">
                                    <div><img src="img/down-arrow.png" alt="down-arrow"></div>
                                    <h3>43%</h3>
                                    <span>reduction in the risk of recurrence or death HR*=0.57 (98% CI: 0.43-0.74); P<0.0001<sup>‚Ä†</sup></span>
                                </div>
                            </div>
					  
                    </div><!--end col12-->

                    <div class="col-12 col-md-9 col-lg-5 mt-ipad-setting offset-lg-1 mx-md-auto">

                        <!-- <div class="reduction-block px-2 pl-4 mb-4 d-flex align-item-center"> -->
                            <!-- <h2 class="mb-0">51% <i class="fas fa-arrow-down"></i> <span>reduction in the risk of death</span></h2> -->
                        <!-- </div> -->
                        
                        <div class="reduction-block px-2 pl-4 mb-4 d-flex align-item-center present_div_desk text-left recurrence-block">
                            <h2 class="mb-0"><img src="img/down-arrow.png" alt="down-arrow"> 43%<span>reduction in the risk of recurrence or death HR*=0.57 (98% CI: 0.43-0.74); P<0.0001<sup>‚Ä†</sup></span></h2>
                        </div>
                        
                        <div class="reduction-block px-2 pl-4 mb-4 d-flex align-item-center present_div_desk text-left recurrence-block reduction-block-only-mobile">
                            <h2 class="mb-0"><img src="img/down-arrow.png" alt="down-arrow"> 43%<span>reduction in the risk of recurrence or death</span></h2>
                        </div> 

 
                         <div class="rate-column wo-heading">
						 
                            <div class="container-fluid progress_sec">
								<div class="plat_pem_sec">
									<p class="keytruda_plat_text"><strong class="semi-bold">For patients with PD-L1 positive tumours:</strong><sup class="semi-bold">1,2</sup> <br> RFS HR (KEYTRUDA<sup>&reg;</sup> vs. placebo) was 0.54 (95% CI: 0.42, 0.69)</p>
									
								</div>
                                <div class="row response-chart-holder first_chart_holder response-chart-else">
                                   
                                    <div class="left-chart-response col text-center">
                                                <div class="progressbar" data-animate="false">
                                                <div class="circle" data-percent="46">
                                                <div></div>
                                                </div> 
                                                </div> 
										<h5 class="text-second mt-1">reduction in the risk of recurrence or death <br> <!-- <small>RFS HR=0.54 (95% CI: 0.42, 0.69); P<0.001</small> --></h5>
                                    </div><!--end left chart response-->

                                    <!-- <div class="response-chart-header d-m-block">
                                       <h3 class="plat_pem_text">PD-L1 negative patients <br><small>(pre-defined subgroup analyses):</small></h3>
                                    </div> -->

                                    <!-- <div class="right-chart-response col text-center">
                                          <div class="progressbar1" data-animate="false">
                                                <div class="circle1" data-percent="53">
                                                <div></div>
                                                </div> 
                                                </div>
                                         <h5 class="text-second mt-3">reduction in the risk of recurrence or death <br> <small>HR=0.47 (95% CI: 0.26, 0.85)</small></h5>
										 
                                    </div> -->

                                </div><!--end flex container-->							
                            </div><!--end container fluid-->  

                       </div><!--end rate column-->
                       <div class="response_detail_list list-modified">
                        <h4 class="secondary-page-header text-center my-4"> RFS benefit for KEYTRUDA<sup>&reg;</sup> vs. placebo was observed regardless of tumour PD-L1 expression or BRAF mutation status.<sup>1</sup></h4>

                        <ul>
                            <li><span>*</span> Based on the stratified Cox proportional hazard model.</li>
                            <li>‚Ä† p-value (based on stratified log rank test) is compared with 0.008 of the allocated alpha for this interim analysis.</li>
                           
                        </ul>
                      </div>
                    </div><!--end col12-->
                </div><!--end row-->



            </div><!--end container-->

        </section><!--end page banner content section-->
        <!--section ends here-->


        <!--section starts here-->
        
        <!--section ends here-->

        <!--section starts here-->
        <section id ="section-3" class="page-banner-content safety w-100 background-properties back-effect line-common-section">
            <div class="section-content-holder w-100">
                <div class="container draw-white main_safity_contain py-100-fixer">
                    <div class="row main_safity">
                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span> Safety Profile</h2>
                            <p class="page-lead"> In this section, the safety data from the pivotal KEYNOTE-054 study is presented showing the adverse event profile of KEYTRUDA<sup>¬Æ</sup> in patients with stage III resected melanoma.   
                                </p>
                        </div><!--end col md-->
                    </div><!--end row-->
                </div><!--end container-->
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 adverse-event line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-8 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Adverse Events</h2>
                        <p class="common-text">KEYTRUDA<sup>¬Æ</sup> was generally well tolerated in patients with stage III resected melanoma.</p>
                    </div><!--end col-->
                </div><!--end row-->

                <div class="row mt-4">
                    <div class="col-12">
                        <h4 class="secondary-page-header">Most common treatment-related AEs with KEYTRUDA<sup>&reg;</sup> adjuvant therapy (‚â•15% of patients)<sup>1</sup></h4>
						<div class="table-responsive">
                       <table class="table table-striped table-responsive-sm custom-table mt-4 hand-icon-table">

                        <thead class="thead-dark">
                          <tr>
							<th colspan="1"></th>
                            <th colspan="3">KEYTRUDA<sup>¬Æ</sup> 200 mg every 3 weeks (n=509)</th>
                            <th colspan="3">Placebo (n=502)</th>
                          </tr>
                        </thead>

                        <tbody> 
                          <tr class="first-row">
                            <td>Adverse Reaction</td>
							<td>Any Grade</td>
                            <td>Grade 3</td>
                            <td>Grade 4</td>
                            <td>Any Grade</td>
                            <td>Grade 3</td>
                            <td>Grade 4</td>
                          </tr>

                           <tr>
                            <td>Diarrhea</td>
                            <td>18.5%</td>
                            <td>0.6%</td>
                            <td>0.2%</td>
                            <td>16.3%</td>
                            <td>0.6%</td>
							<td>-</td>
                          </tr>

                           <tr>
                            <td>Fatigue</td>
                            <td>28.1%</td>
                            <td>0.8%</td>
                            <td>-</td>
                            <td>26.9%</td>
                            <td>0.4%</td>
							 <td>-</td>
                          </tr>

                          <tr>
                            <td>Pruritus</td>
                            <td>16.7%</td>
                            <td>-</td>
                            <td>-</td>
                            <td>9.8%</td>
                            <td>-</td>
							<td>-</td>
                          </tr>
                        </tbody><!--end tbody-->
                      </table><!--end table-->
                      <p class="chart-content-small">Adapted from the KEYTRUDA<sup>&reg;</sup> Product Monograph.<sup>1</sup></p>    
                    </div>
                   
                        <div class="download_table mt-4 mb-3">
                            <a href="img/Adverse-Events-updated.pdf" target="_blank" download class="btn button-second">
                            Download Table  <img src="img/download_table.png" alt="download_table"></a>
                                <a href="#" class="zoom_icon" data-toggle="modal" data-target="#tableZoomAdverse"><img src="img/zoom_icon.png" alt="zoom"></a>
                                       
                                    <!-- Modal -->
                                <div class="modal fade custom-zoom-modal" id="tableZoomAdverse" tabindex="-1" role="dialog" aria-hidden="true">
                                    <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                        <div class="modal-content"> 
                                            <div class="modal-body"> 
                                                <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                        <span aria-hidden="true">&times;</span>
                                                    </button>
                                                    <img src="img/adverse-event-updated.png" alt="table" class="img-fluid">
                                            </div>
                                        </div>
                                    </div>
                                </div>
                        </div> 
                        <div class="row">
                        <div class="col-lg-8 col-sm-12">
                            <div class="adver_event mt-2">
                                <p>AEs were <strong class="semi-bold">generally similar</strong> to those in patients with unresectable or metastatic melanoma or non-small cell lung cancer (NSCLC).<sup>1</sup></p>
                            </div> 
                        </div>                  
                    </div>
                    </div><!--end col12-->
                </div><!--end row-->


            </div><!--end container-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section id="section-4" class="page-banner-content dosing w-100 background-properties back-effect line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white py-5 py-100-fixer">
                    <div class="row">
                        <div class="col-md-12 col-lg-7 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span> Dosing</h2>
                            <p class="page-lead">This section presents KEYTRUDA<sup>&reg;</sup>'s recommended dose and administration for the adjuvant treatment of melanoma.</p>
                        </div><!--end col md-->
                    </div><!--end row-->
                </div><!--end container-->
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 recommended-dose line-common-section">
            <div class="container draw-green recom_contain py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Recommended Dose</h2>
                    </div><!--end col-->
                </div><!--end row-->

                <div class="row mt-5">
                    <div class="col-sm-6 col-12 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-5.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div><!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">200 mg fixed dose by IV infusion</p>
                        </div><!--end service block content-->
                    </div><!--end col sm4-->

                     <div class="col-sm-6 col-12 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-6.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div><!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">Over 30 minutes</p>
                        </div><!--end service block content-->
                    </div><!--end col sm4-->

                     <div class="col-sm-6 col-12 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-7.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div><!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">Every 3 weeks</p>
                        </div><!--end service block content-->
                    </div><!--end col sm4-->
                </div><!--end row-->
			 
                <div class="row">
                    <div class="col-12 col-sm-12 col-lg-12">
                        <div class="recommed_para">
                        <p class="product_mono_para">Treatment for up to 1 year <strong class="semi-bold">or</strong> until disease recurrence <strong class="semi-bold">or</strong> unacceptable toxicity.<sup>1</sup></p>
                        <p class="product_mono_para">For more information about dosing and dose modifications, please see the <a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf" target="_blank">Product Monograph.</a></p>
                    </div>
                    </div>
                </div>
            </div><!--end container-->
			
        </section><!--end page banner content section-->
        <!--section ends here-->

         <!--section starts here-->
        <section class="page-banner-content merck-care w-100 background-properties back-effect light line-common-section" id="section-5">

            <div class="section-content-holder w-100">
                <div class="container draw-white oncology_program_sec py-100-fixer">
                    <div class="row">
                        <div class="col-md-12 col-lg-9 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span>MERCK Care<sup>‚Ñ¢</sup> Oncology Program </h2>
                            <p class="page-lead">The Merck Care<sup>TM</sup> Oncology Program offers free, confidential patient-assistance services for patients who have been prescribed KEYTRUDA<sup>¬Æ</sup>. Please see enrollment form for more details on inclusion criteria.</p>
                        </div><!--end col md-->
                        
                    </div><!--end row-->

                </div><!--end container-->
            </div><!--end section content holder-->
        </section><!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 oncology-section line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <!-- <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle" id="line-ends"></span>Program services</h2>
                    </div>
                </div> -->

                <div class="row align-items-start program_services_sec">
                    <div class="col-md-12 col-sm-12 col-12 pr-lg-5 pr-md-0 col-lg-6">
                         <h2 class="common-page-heading"><span class="pulsating-circle" id="line-ends"></span>Program Services</h2>
                        <h4 class="secondary-page-header mt-4">Services may include, depending on eligibility:</h4>
                        <ul class="custom-listing">
                            <li>Reimbursement</li>
                            <li>Compassionate assistance</li>
                            <li>Financial assistance</li>
                            <li>Nursing support services</li>
                        </ul><!--end custom listing-->
                         <p class="text-second">These services will be presented to the patient during an initial call with the Program nurse.</p>
						 <p class="text-second">The objective of the Merck Care‚Ñ¢ Oncology Program is to help ensure that patients receive the support they need during KEYTRUDA<sup>¬Æ</sup> therapy. See conditions disclosed in the enrollment form.</p>
                    </div><!--end col6-->

                    <div class="col-md-12 col-sm-12 col-lg-6 col-12">
                        <ul class="list-group custom-list-group footer-listing-mobile-setting">
						  <li class="list-group-item"><span class="list_img"><img src="img/watch_icon.png" alt="mobile" class="img-fluid watch_icon_desktop"><img src="img/Clock_Icon.png" alt="mobile" class="img-fluid watch_icon_mobile"></span> <span class="program_ser_content"><span>Hours of operation:</span> <br><span class="contact_detail">Monday to Friday from 8 am to 8 pm EST</span></span></li>

                          <li class="list-group-item"><span class="list_img"><img src="img/mob-icon.png" alt="mobile" class="img-fluid phone-icon"></span> <span class="program_ser_content"><span>Contact us:</span> <span class="contact_detail contact_text_brdr"><a href="tel:18555499416">1-855-549-9416</a></span></span></li> 

                            <li class="list-group-item"><span class="list_img"><img src="img/email-icon.png" alt="email" class="img-fluid"></span><span class="program_ser_content"> <span>Email us:</span> <span class="contact_detail contact_text_brdr"><a href="mailto:keytruda@bayshore.ca">keytruda@bayshore.ca</a></span></span></li> 

                           <li class="list-group-item"><span class="list_img"><img src="img/fax-icon.png" alt="fax" class="img-fluid"></span> <span class="program_ser_content"><span>Fax us:</span> <span class="contact_detail">1-855-549-9415</span></span></li>

                           <li class="list-group-item"><div class="d-block enrollment_text"><p><b>MERCK Care‚Ñ¢ Oncology Program Enrollment Form</b> <br> Fill out the form to enroll KEYTRUDA<sup>&reg;</sup> patients in the Merck Care‚Ñ¢ Oncology Program:</p></div> 
                            <a href="img/Merck_Care_Oncology_Enrollement_Form.pdf" class="btn button-primary text-capitalize download_now_btn" target="_blank" download>Download Now <img src="img/np_save.png" alt="download_icon" class="white-np"><img src="img/np-save-active.png" alt="download icon" class="active-np"></a></li> 

                        </ul><!--end list group-->
						<p class="merck_cana_text">‚Ñ¢Merck Canada Inc.</p>
                    </div><!--end col6-->
                </div><!--end row-->
            </div><!--end container-->
        </section><!--end page banner content section-->
        <!--section ends here-->

         <!--section starts here-->
        <section class="page-common-section w-100 view-merck second_view_merck">
            <div class="container py-5">

                <div class="row view_merck_row">
                    <div class="col-12 col-md-12 text-center view_merck_colum">
                       <h2 class="common-page-heading font-weight-bold text-white mb-4">Learn more about Keytruda<sup>&reg;</sup></h2>
                        
                        <a class="btn button-primary button-white visit_button" href="https://www.merckconnect.ca/en/login.xhtml " target="_blank">Visit Merck Connect <img src="img/visit_arrow.png" alt="arrow" class="arrow-blue"><img src="img/button-white-arrow.png" alt="arrow" class="arrow-white"></a>  
                    </div><!--end col-->
                </div><!--end row-->

            </div><!--end container-->
        </section><!--end page banner content section-->
		<section class="footer_refrence_text">
			<div class="container">
               <p class="refre_top_text"><strong>CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group Performance Status; HR=hazard ratio; PD-L1=programmed death ligand 1.</strong></p>

			<div class="refrence_text">
			<ul>
<li><strong>References: </strong></li> 
<li><strong>1.</strong> KEYTRUDA<sup>&reg;</sup> Product Monograph. Merck Canada Inc. April 26, 2019. </li> 
<li><strong>2.</strong> Eggermont AMM, Blank CU, Mandala M, <i>et al.</i> Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>N Eng J Med.</i> 2018;378:1789-1801.</li> 
			</ul>
			<ul>
				<li>¬Æ Merck Sharp & Dohme Corp. Used under license.</li>
				<li>¬© 2019 Merck Canada Inc. All rights reserved.</li>
				<li>Merck Canada Inc., </li>
				<li>16750 Trans Canada Highway,</li>
				<li>Kirkland, Quebec, Canada, H9H 4M7</li>
			</ul>
			<div class="refre_div">
				<p class="refre_top_text pass_text">CA-KEY-00028 </p>
				<ul class="logo_list">
					<li><img src="img/Keytruda-logo.png" alt="logo1"></li> 
					<li><img src="img/Merck-logo_std_CMYK.png" alt="logo2"></li> 
					<li><img src="img/Paab.png" alt="logo3"></li> 
					<li><img src="img/InnovativeMeds.png" alt="logo4"></li> 
				</ul>
			</div>
			</div>
			
			</div>
		</section>
        <!--section ends here-->
    </main><!--end site body-->
    <!--==========================site naub body starts here=====================================-->

    <!--==========================site footer starts here=====================================-->
    <footer class="footer" id="siteFooter">
      <div class="container">

          <div class="row">
              <div class="col-12">
                <ul class="footer-links list-inline">
                    <li class="list-inline-item"><a href="#section-1">KEYTRUDA<sup>&reg;</sup></a></li>
                    <li class="list-inline-item"><a href="#section-2">Efficacy</a></li>
                    <li class="list-inline-item"><a href="#section-3">Safety profile</a></li>
                    <li class="list-inline-item"><a href="#section-4">Dosing</a></li>
                    <li class="list-inline-item"><a href="#section-5">Merck care<sup>TM</sup> Oncology Program</a></li>                    
                    <li class="list-inline-item"><a href="https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf" target="_blank">Product Monograph</a></li> 
                    
                    <li class="list-inline-item"><a href="#" data-toggle="modal" data-target="#safety-popup">Safety Information</a></li> 
                    <li class="list-inline-item"><a href="https://www.merck.ca/en/home/" target="_blank">MERCK.CA</a></li>
                </ul><!--end footer links-->

                <div class="footer_contact_us">
					<h3><b>Contact us:</b> <a href="mailto:medinfocanada@merck.com">medinfocanada@merck.com</a></h3> 
					<ul>
						<li><a href="#" data-toggle="modal" data-target="#termuse-popup">Terms of Use</a></li>
						<li><a href="https://www.merck.ca/en/privacy/" target="_blank">Privacy policy</a></li>
					</ul>
				</div>
              </div><!--end col 12-->
          </div><!--end row-->
      </div><!--end container-->

      <!-- safety popup-->

        <!-- The Modal -->
  <div class="modal popup-show" id="safety-popup">
    <div class="modal-dialog">
      <div class="modal-content">
      
        <!-- Modal Header -->
        <div class="modal-header">
          <h4 class="modal-title">Safety information </h4>
          <button type="button" class="close" data-dismiss="modal"><img src="img/cross-white.png"></button>
        </div>
        
        <!-- Modal body -->
        <div class="modal-body">
          <div class="inner-modal-body">
            <div class="uppper-use-sec">
             <h3 class="safety-h3"><strong><u>Indications and clinical use:</u></strong></h3>
              
              <div class="under-accord-sec">
              <p><sup>Pr</sup>KEYTRUDA<sup>¬Æ</sup> (pembrolizumab) is also indicated for:</p>
                    <li>Treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.</li>
                    <li>Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.</li>

             

              <p>The safety and efficacy of KEYTRUDA<sup>¬Æ</sup> has not been established for pediatric patients with conditions other than relapsed or refractory PMBCL.</p>
              </div>
              <div class="rel-warning-sec">
               <h3 class="safety-h3"><strong><u>Relevant warnings and precautions:</u></strong></h3>
               <li>Immune-mediated adverse reactions including severe and fatal cases: </li>
                <ul>
                    <li>Pneumonitis</li>
                    <li>Colitis</li>
                    <li>Hepatitis</li>
                    <li>Nephritis and renal dysfunction</li>
                    <li>Endocrinopathies including hypophysitis, type 1 diabetes mellitus and thyroid disorders</li>
                    <li>Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis</li>
                </ul>
               <li>Other immune-mediated adverse events, including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (including exacerbation), vasculitis, Guillain-Barr√© syndrome, hemolytic anemia and pancreatitis </li>
               <li>Myocarditis</li>
               <li>Solid organ transplant rejection </li>
            <li>Increased mortality in patients with multiple myeloma when added to a thalidomide analogue and dexamethasone </li>
               <li>Complications of allogeneic Hematopoietic Stem Cell Transplant (HSCT) in classical Hodgkin Lymphoma </li>
               <li>Severe infusion-related reactions, including hypersensitivity and anaphylaxis </li>
               <li>Embryofetal toxicity </li>
                <li>Not recommended in pregnant women </li>
               <li>In nursing women, a decision should be made whether to discontinue breast-feeding or KEYTRUDA<sup>¬Æ</sup> taking into account the benefit of breast-feeding for the child and the benefit of KEYTRUDA<sup>¬Æ</sup> therapy for the woman </li>
               <li>Has not been studied in patients with moderate or severe hepatic impairment </li>
               <li>Has not been studied in patients with severe renal impairment </li>
            <li>Monitor liver and thyroid function tests and electrolytes during treatment </li>

              </div>

              <div class="bottom-info-sec">
               <h3 class="safety-h3"><strong><u>For more information: </u></strong></h3>
               <p>Please consult the KEYTRUDA<sup>¬Æ</sup> product monograph at <a href="https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf" target="_blank">https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf</a> for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.</p>
               <p>The product monograph is also available by calling <a href="tel:1-800-567-2594">1-800-567-2594</a>.</p>
              </div>
            </div>
          </div>
        </div>
        
        
      </div>
    </div>
  </div>
    <!-- safety popup-->

     <!-- The Modal -->
  <div class="modal" id="termuse-popup">
    <div class="modal-dialog">
      <div class="modal-content">
      
        <!-- Modal Header -->
        <div class="modal-header">
          <h4 class="modal-title">TERMS OF USE EFFECTIVE AS OF MARCH 1, 2019 </h4>
          <button type="button" class="close" data-dismiss="modal"><img src="img/cross-white.png"></button>
        </div>
        
        <!-- Modal body -->
        <div class="modal-body">
          <div class="inner-modal-body">
            <div class="uppper-use-sec">
            
              <div class="bor-accord-sec">
            <p>PLEASE READ AND REVIEW THE FOLLOWING TERMS OF USE AGREEMENT CAREFULLY BEFORE USING THIS WEB SITE <a href="https://www.merck.ca/en/home/" target="_blank">merck.ca</a> (THE "Web Site") OWNED AND OPERATED BY MERCK CANADA INC., A SUBSIDIARY OF MERCK SHARP & DOHME CORP., KENILWORTH, NJ, USA ("Merck" or "Us"). By using this Web site, you agree to this Terms of Use Agreement. If you do not agree, please exit and disregard the information contained herein.</p>

                <p>This Web site is controlled and operated by Merck from Kirkland, Quebec and its content is designed to comply with Canadian laws and regulations. This site and these terms shall be governed by the laws of Quebec and the applicable laws of Canada without reference to principles of conflict of laws. You agree to be bound by such laws.</p>

                <p><strong>1. Acceptance.</strong> By using this Web site, you agree to be bound by and to comply with this Terms of Use Agreement. Merck reserves the right to change these terms from time to time, as it deems to be necessary. We will always post notice of those changes, and the date that they become effective, within the current Terms of Use Agreement on the Web site. You may view the current applicable version of this Terms of Use Agreement at any time through a link at the bottom of each page within this Web site.</p>

 <p><strong>2. Scope.</strong> The terms of use set forth in this agreement apply only to your use of this Web site. Merck operates other Web sites that are covered by their own conditions as specified within those Web sites.</p>

 <p><strong>3. Medical Information/Conditions.</strong> While there may be information on this Web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health care provider. We do not offer personalized medical diagnosis or patient-specific treatment advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can provide medical advice and determine if a product described in this, or any, Web site is appropriate for you.</p>

<p>PLEASE CONSULT WITH YOUR DOCTOR OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS, OR ANY OTHER, WEB SITE.</p>


               <p><strong>4. Description of Services.</strong> This Web site contains material about Merck and its various initiatives and products. Certain sections of this Web site are intended for particular audiences including Merck's employees, customers and shareholders, as well as to members of the health care community and the general public. Please feel free to browse this Web site, as appropriate. Your access to and use of the information contained herein is subject to this Terms of Use Agreement and all applicable laws. By accessing and browsing this Web site, you accept, without limitation or qualification, this Terms of Use Agreement and acknowledge that it supersedes any other agreement between you and Merck.</p>

               <p><strong>5. Ownership.</strong> Material on this Web site, including but not limited to text, images, illustrations, software, audio clips and video clips, is owned or otherwise provided by Merck, and Merck does not represent or warrant that such material does not infringe the rights of any other person or entity. Trademarks and logos (collectively, "Marks") displayed on this Web site are registered or unregistered Marks of Merck or others, are the property of their respective owners, and may not be used without written permission of Merck or of the owner of such Marks respectively. Any information or material contained on this Web site which may be reproduced pursuant to these terms must bear the proprietary rights notices which originally appear on or in conjunction with such information or material.</p>

               <p><strong>6. Representation.</strong> As a user of this Web site, you are liable for the accuracy of the information that you provide to us, including, but not limited to, your professional license number and your professional representation, if applicable.</p>

               <p>Should you respond with information including feedback or data such as questions, comments, suggestions, or the like regarding the content of this Web site, such information shall be deemed to be non-confidential, unless as may be required under applicable law, and Merck shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. You also warrant that any information or material including ideas, concepts, know-how or
techniques contained in this information which you provide to Merck electronically through your access to or usage of this website does not infringe the rights of any person or entity. Merck shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.</p>

<p><strong>7. Privacy.</strong> Please refer to <a href="https://www.merck.ca/en/privacy/" target="_blank">Commitment to Privacy</a> for information on how the company protects your personal information.</p>

<p><strong>8. Third Party Content and Links to Other Web sites.</strong> This Web site or other Merck Internet Web sites to which this Web Site links may contain information brought to you by third parties. This Web site may also provide links to other Internet websites. Merck assumes no responsibility for information provided by third parties or the content of other web sites to which Merck provides links. Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practice of standards of any non-Merck sources. Any links to other sites are provided merely as a convenience to the users of this Web site. Those Internet web sites are governed by their own terms of use displayed on the respective web sites.</p>

<p><strong>9. Disclaimer of Warranties and Limitation of Liability.</strong> Merck has taken reasonable measures to ensure that the information contained within this Web site is reliable; however, by using this Web site, you accept the information, products and services provided herein "AS IS." Merck makes no express or implied warranty regarding the accuracy, content, completeness, reliability, operability, or legality of this Web Site and/or of information contained within this Web site. Merck exerts reasonable efforts to provide a satisfactory service, but we do not warrant that the Web Site will be accessible at any time without interruption, that it will be free of errors, breakdowns, failures, any harmful or damaging content or that it will be secure or protected from unauthorized access.</p>

<p>Merck may not, under any circumstances, be held responsible for any damage, loss, costs or expenses directly or indirectly related to the access or use of this Web site and/or its content.</p>

<p><strong>10. Consequences.</strong> If your violation of the Terms of Use Agreement causes harm to others, you agree to indemnify and hold Merck harmless from and against any and all loss, damage, or expense. If any dispute arises between us regarding this Agreement or your use of this Web site, it shall be resolved through good faith negotiations between the parties. If such efforts prove unsuccessful, all such controversies, claims, or disputes shall be submitted to the jurisdiction of the courts of Quebec.</p>


              </div>
            </div>
          </div>
        </div>
        
        
      </div>
    </div>
  </div>
    <!-- safety popup-->

    </footer><!--end site footer-->
    <!--==========================site footer starts here=====================================-->    


    <!-- External JavaScript goes here-->
    <script src="js/bootstrap.bundle.min.js"></script>
    <script src="js/slick.min.js"></script>
    <script src="js/jQuery-inView.min.js"></script>
    
    <!--custom js-->
    <script src="js/main.js"></script>

	
<script>
var navHeight=$('header#siteHeader').height();
var navHeightnew=$('header#siteHeader').height() + 20;
$('a.nav-link').on('click', function () {

  var $el = $(this)
    , id = $el.attr('href');
  
  jQuery("body, html").animate({ 
      scrollTop: jQuery( id ).offset().top - navHeight	
    }, 10);
    return false;
	
});
 var scrollLink = $('.scroll');
  $(window).scroll(function() {
 
    var scrollbarLocation = $(this).scrollTop();
    
    scrollLink.each(function() {
      
      var sectionOffset = $(this.hash).offset().top - navHeightnew;

      if ( sectionOffset <= scrollbarLocation ) {
	   $('a.nav-link').removeClass('active');
        $(this).addClass('active');
     /*   $(this).siblings().removeClass('active');*/
      }
    })
    
  });
</script>
 

  </body>
</html>